Evidence map›Paper›PMID 36780824›Full record

ArticleOral oncology2023

The collateral impact of the COVID-19 pandemic on HPV-positive oropharyngeal cancer diagnosis.

Yashi Ballal, Maru Gete, Jie Su, Brian O'Sullivan, John N Waldron, Jonathan Irish, Jolie Ringash, John Kim, Scott Bratman, John Cho and 10 more

Open access · greenAbstract read
In one paragraph

Article in Oral oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Changes in management of head and neck malignancies during the COVID-19 pandemic.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2024
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 1 country.

Yashi BallalThe Michener Institute/University of Toronto, Toronto, Canada; Department of Radiation Therapy, Princess Margaret Cancer Centre/University of Toronto, Toronto, Canada. Electronic address: yashi.ballal@mail.utoronto.ca.
Maru GeteDepartment of Otolaryngology - Head and Neck Surgery/Surgical Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Canada. Electronic address: marugete@gmail.com.
Jie SuDepartment of Biostatistics, Princess Margaret Cancer Centre/University of Toronto, Toronto, Canada. Electronic address: Susie.Su@uhnresearch.ca.
Brian O'SullivanDepartment of Otolaryngology - Head and Neck Surgery/Surgical Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Canada; Department of Radiation Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Canada. Electronic address: Brian.OSullivan@rmp.uhn.ca.
John N WaldronDepartment of Otolaryngology - Head and Neck Surgery/Surgical Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Canada; Department of Radiation Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Canada. Electronic address: John.Waldron@rmp.uhn.ca.
Jonathan IrishDepartment of Otolaryngology - Head and Neck Surgery/Surgical Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Canada. Electronic address: Jonathan.Irish@uhn.ca.
Jolie RingashDepartment of Otolaryngology - Head and Neck Surgery/Surgical Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Canada; Department of Radiation Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Canada. Electronic address: Jolie.Ringash@rmp.uhn.ca.
John KimDepartment of Radiation Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Canada. Electronic address: John.Kim@rmp.uhn.ca.
Scott BratmanDepartment of Radiation Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Canada. Electronic address: Scott.Bratman@rmp.uhn.ca.
John ChoDepartment of Radiation Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Canada. Electronic address: John.Cho@rmp.uhn.ca.
Andrew J HopeDepartment of Radiation Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Canada. Electronic address: Andrew.Hope@rmp.uhn.ca.
Ali HosniDepartment of Radiation Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Canada. Electronic address: Ali.Hosni@rmp.uhn.ca.
John de AlmeidaDepartment of Otolaryngology - Head and Neck Surgery/Surgical Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Canada. Electronic address: John.DeAlmeida@uhn.ca.
David P GoldsteinDepartment of Otolaryngology - Head and Neck Surgery/Surgical Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Canada. Electronic address: David.Goldstein@uhn.ca.
Ian WitterickDepartment of Otolaryngology - Head and Neck Surgery/Surgical Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Canada. Electronic address: Ian.Witterick@sinaihealth.ca.
Eric MonteiroDepartment of Otolaryngology - Head and Neck Surgery/Surgical Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Canada. Electronic address: Eric.Monteiro@sinaihealth.ca.
Li TongDepartment of Radiation Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Canada. Electronic address: Li.Tong@rmp.uhn.ca.
Wei XuDepartment of Biostatistics, Princess Margaret Cancer Centre/University of Toronto, Toronto, Canada. Electronic address: Wei.Xu@uhnresearch.ca.
Shao Hui HuangDepartment of Radiation Therapy, Princess Margaret Cancer Centre/University of Toronto, Toronto, Canada; Department of Otolaryngology - Head and Neck Surgery/Surgical Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Canada; Department of Radiation Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Canada. Electronic address: Shaohui.Huang@rmp.uhn.ca.
Ezra HahnDepartment of Radiation Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Canada. Electronic address: Ezra.Hahn@rmp.uhn.ca.
Princess Margaret Cancer Centre · CAUniversity of Toronto · CAMichener Institute · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe aim to assess the potential impact of the COVID-19 pandemic on diagnostic delays in HPV-positive oropharyngeal cancer (OPC), and to describe their underlying reasons.

methodsAll HPV + OPC referred to a tertiary cancer centre and diagnosed between June-December 2019 (Pre-Pandemic cohort) vs June-December 2020 (Pandemic cohort) were reviewed. TNM classification, gross-tumor-volumes (GTV) and intervals between sign/symptom onset and treatment initiation were compared between the cohorts. Reasons for delay (>6 months from onset of signs/symptoms to a positive biopsy of the primary tumor, or a delay specifically mentioned in the patient chart) in establishing the diagnosis were recorded per clinician's documentation, and categorized as COVID-related or non-COVID-related.

resultsA total of 157 consecutive HPV + OPC patients were identified (Pre-Pandemic: 92; Pandemic: 65). Compared to the Pre-Pandemic cohort, Pandemic cohort patients had a higher proportion of N2-N3 (32 % vs 15 %, p = 0.019) and stage III (38 % vs 23 %, p = 0.034) disease at presentation. The differences in proportions with > 6 months delay from symptom onset to establishing the diagnosis (29 % vs 20 %, p = 0.16) or to first treatment (49 % vs 38 %, p = 0.22) were not statistically different. 47 % of diagnostic delays in the Pandemic cohort were potentially attributable to COVID-19.

conclusionWe observed a collateral impact of the COVID-19 pandemic on HPV + OPC care through more advanced stage at presentation and a non-significant but numerically longer interval to diagnosis. This could adversely impact patient outcomes and future resource allocation. Both COVID-19-related and unrelated factors contribute to diagnostic delays. Tailored interventions to reduce delays are warranted.

Indexed as

COVID-19Oropharyngeal NeoplasmsPapillomavirus InfectionsCOVID-19 TestingHumansPandemicsRetrospective StudiesCOVID-19DiagnosisHuman PapillomavirusOropharyngeal CarcinomaPandemicStaging

Identifiers

PMID36780824
PMCPMC9894773
OpenAlexW4319160798

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.